• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GlaxoSmithKline plc

New GSK chief exec: Fewer, more focused drug programs as generic competition looms

April 26, 2017 By Sarah Faulkner

GlaxoSmithKline

In her 1st comments since taking the helm on April 1st, GlaxoSmithKline‘s (NYSE:GSK) new chief executive Emma Walmsley said that her priority is the company’s pharmaceuticals unit, where she wants to lead fewer but bigger new drug launches. “We’d like to have probably fewer and more focused priorities, to have bigger launches,” she told reporters, according […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, Mylan

Innoviva bows to pressure from Sarissa hedge fund, to review executive pay

April 14, 2017 By Brad Perriello

Innoviva

Innoviva (NSDQ:INVA) said yesterday that it plans to review its costs including the salaries of its top executive and board, bowing to pressure from hedge fund and activist investor Sarissa Capital Management. Two weeks ago the fund demanded that Innoviva cut CEO Michael Aguiar’s pay to less than $500,000 a year; Aguiar’s total compensation in 2015 […]

Filed Under: Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Innoviva, Sarissa Capital Management

Mylan shares down -3% after FDA rejects Advair generic

March 29, 2017 By Sarah Faulkner

Mylan

Shares in Mylan (NSDQ:MYL) dropped -3% to $40.46 apiece today after the FDA rejected its Abbreviated New Drug Application for the generic version of GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus. The Canonsburg, Penn.-based company said it is “in the process of reviewing this response and will provide an update on its application as soon as practicable once it has […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Mylan

Trump FDA pick to recuse himself from agency decisions involving 20 companies

March 29, 2017 By Sarah Faulkner

FDA

Donald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY). Gottlieb has received millions of dollars for his roles as advisor, paid speaker […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat Tagged With: Biogen Idec, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Merck

Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016

March 22, 2017 By Sarah Faulkner

Prescription drugs

Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb Co., C.R. Bard, Catalent, Eli Lilly & Co., GlaxoSmithKline plc, Medtronic, Merck, Mylan, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

GlaxoSmithKline, Innoviva tout data for Relvar Ellipta inhaled drug combo

February 23, 2017 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy in patients with asthma. The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function. Patients who switched to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Innoviva

Collecting purposeful data in the era of connected health devices

February 16, 2017 By Sarah Faulkner

Collecting purposeful data in the era of connected health devices

Connectivity, one of the newest buzzwords in the medical device lexicon, is becoming more and more integral to device design and development. Research shows that connected health devices can improve patient outcomes by increasing adherence and reducing dosing variability. Mark David Tuckwell, head of electronics, software & systems at Sagentia, says connected device can also provide crucial information to help […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Adherium, Baxter International, Becton Dickinson, Companion Medical, GlaxoSmithKline plc, Propeller Health, Sagentia, Sanofi-Aventis

Early collaboration is key in drug-device development, experts say

February 15, 2017 By Sarah Faulkner

Industry leaders talk partnerships, collaboration in drug delivery

While pharmaceutical companies and medical device firms know that working together is a vital part of doing business, they “live in 2 different world in many ways,” Minnetronix co-founder Dirk Smith said last week at the annual Drug Delivery Partnerships conference. From development timelines to regulatory approval pathways, it can sometimes seem like pharma and medtech companies are […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International, Becton Dickinson, GlaxoSmithKline plc, Minnetronix, Sanofi-Aventis

Novo Nordisk puts $145m into U.K. research center

January 30, 2017 By Sarah Faulkner

Novo Nordisk

(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit. The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk

GSK launches phase III trial for inhaled triple combination therapy

December 19, 2016 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that they launched a phase III trial evaluating the triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with asthma. The companies’ triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day using GSK’s […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS